| Literature DB >> 12875366 |
Mi-Sun Kim1, Ho-Jeong Na, Seung-Woo Han, Jong-Sik Jin, Un-Yong Song, Eon-Jeong Lee, Bong-Keun Song, Seung-Heon Hong, Hyung-Min Kim.
Abstract
Mast cells are key as effector cells in the early phase allergic inflammation and in diverse immunological and pathological processes. Forsythia fructus (F. fructus) has used as a traditional medicine for inflammatory diseases. In the present study, we determined the effect of F. fructus extracts on compound 48/80-induced paw oedema and vascular permeability in vivo. In addition, we investigated in vitro whether F. fructus has inhibitory effects on compound 48/80-induced histamine releases from rat peritoneal mast cells (RPMC), and on phorbol 12-myristate 13-acetate (PMA) plus A23187-induced tumor necrosis factor-alpha (TNF-alpha) releases from human mast cells (HMC-1). In mice orally administrered F. fructus (100 microg/g) for 1 h, compound-48/80-induced oedema and vascular permeability were significantly reduced rather than those receiving intravenous injection of ketotifen, mast cell stabilizer. F. fructus dose-dependently inhibited the histamine release induced by compound 48/80 from RPMCs. Moreover, F. fructus had no cytotoxic effects on cell viability and had inhibitory effects on TNF-alpha secretion from HMC-1. These results suggest that F. fructus is a potential herb medicine for treatment of inflammatory diseases through downmodulating mast cell activation.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12875366 DOI: 10.1023/a:1023865727780
Source DB: PubMed Journal: Inflammation ISSN: 0360-3997 Impact factor: 4.092